# TB-500 Research: What the Thymosin Beta-4 Studies Measured | TB-500

> TB-500 research, sourced study by study: wound healing, cardiac and stroke models, angiogenesis, hair growth, the tumor safety signal — with the full-length thymosin beta-4 caveat marked throughout.

Each finding logged with its species, dose and route — and a coral mark wherever the data are on full-length thymosin beta-4 rather than the fragment.

## Researched effects of TB-500 in the literature

Across animal and in-vitro studies, thymosin beta-4 — and, to a far lesser extent, its actin-binding fragment — has been investigated for wound and corneal healing, cardiac and neurological repair, angiogenesis, hair-follicle activation and anti-fibrotic effects [5]. A consolidating review framed the protein as an actin-sequestering molecule that "moonlights" to repair injured tissue: binding actin, promoting cell migration, reducing myofibroblast number and scar formation, limiting apoptosis and inflammation, and driving angiogenesis [9]. That breadth is the reason for the research interest.

It is also the reason for the caveats. Almost every result below was generated with full-length Tβ4, and the studies range from foundational to mixed. This page logs them as findings in models — not as benefits, and not as human outcomes.

The two-line summary of `TB-500 benefits` claims you will see elsewhere: the *mechanistic* rationale is real and reproducible in animals; the *human, fragment-specific* efficacy is unproven [12].

## What does the wound-healing research show?

In a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, raised wound contraction (≥11% by day 7) and increased collagen deposition and angiogenesis; as little as 10 pg stimulated keratinocyte migration two- to three-fold [3]. These are among the cleanest effect sizes in the field — and they are full-length Tβ4. The fragment's direct bridge is the db/db and aged-mouse study, where a synthetic actin-binding-domain peptide reproduced wound-repair-relevant activity [7]. Topical Tβ4 (the clinical-grade RGN-259 ophthalmic formulation) also promoted corneal healing and integrity in eye studies that reached human trials [11].

## What does the cardiac research show?

In mice, thymosin beta-4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activated the survival kinase Akt, promoted cardiac and endothelial cell migration, and — after coronary artery ligation — enhanced early myocyte survival and improved cardiac function [2]. That paper is a large part of why Tβ4 entered cardiac-repair development. The counter-evidence belongs on the same line: systemic Tβ4 did not attenuate myocardial ischemia-reperfusion injury in a porcine study, and a registered injectable Tβ4 acute-MI trial completed without launching the molecule clinically. The cardiac story is a promising mechanism with a mixed translation record — and, again, full-length protein, not the 7-mer.

## What do the neurological studies show?

In male Wistar rats with embolic middle cerebral artery occlusion, intraperitoneal thymosin beta-4 improved neurological function. A dose-response study gave 2, 12 and 18 mg/kg starting 24 hours post-stroke, then every three days for four more doses: 2 and 12 mg/kg produced significant improvement from day 14 through day 56 (p<0.05), while 18 mg/kg gave no significant benefit, and the authors modeled an optimal dose near 3.75 mg/kg [4]. A companion report confirmed improved functional outcome after embolic stroke [10]. The non-monotonic curve is the lesson worth carrying: higher was not better, which directly undercuts community "loading" rationales.

## Has TB-500 been studied for hair growth?

Thymosin beta-4 at nanomolar concentrations stimulated hair growth in rats and mice by activating hair-follicle bulge stem cells and increasing their migration, differentiation and MMP-2 expression [9]. This is the parent protein in rodent models. The fragment has not been validated for hair growth in humans, and the effect is reported at very low concentrations, which complicates any extrapolation to research-peptide dosing.

## Does TB-500 promote angiogenesis?

Thymosin beta-4 promotes endothelial migration and new-vessel formation, and recent delivery-system work reports improved vascularized wound repair — a Tβ4-exosome-loaded hemostatic, antibacterial hydrogel enhanced vascularized healing in a 2025 biomaterials study [14], and Tβ4 improved cutaneous-flap survival in rats while activating Wnt/β-catenin signaling [15]. Angiogenesis is, therefore, both a proposed repair mechanism and a safety consideration — because the same pro-vascular activity can support tumor growth.

## Does TB-500 have anti-inflammatory activity?

Thymosin beta-4 has been reported to suppress NF-κB and IL-8 signaling, and 2024 work showed it acts through specialized pro-resolving pathways — linking it to the active resolution of inflammation rather than simple suppression [13]. These are mechanistic and animal/in-vitro findings for the full-length protein. They are not a demonstrated anti-inflammatory effect of the TB-500 fragment in humans.

## Does TB-500 work for muscle recovery?

The athletic-recovery rationale rests on thymosin beta-4 being an exercise-released exerkine that recruits myoblasts to injured muscle. The tempering result is a six-month study in dystrophin-deficient (mdx) mice, where chronic Tβ4 (150 µg twice weekly, intraperitoneal) increased the number of regenerating fibers but did not improve muscle strength, cardiac function or fibrosis. "More regenerating fibers, no strength gain" is the honest summary, and a 2026 *Sports Medicine* review reaches the same broad conclusion for unapproved recovery peptides: favorable animal repair signals, scarce human safety data, potential for serious harm [12].

## Has TB-500 been studied for ligament and tendon repair?

Connective-tissue evidence is thin. Thymosin beta-4 has been reported to enhance healing of a medial collateral ligament injury in rats, and muscle injury induces Tβ4 that acts as a myoblast chemoattractant [9]. These are animal findings. There are no controlled human tendon or ligament trials of the TB-500 fragment [12].

## How quickly do effects appear in studies?

No human timeline is established for the fragment. In the rat full-thickness wound model, thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline [3]. Those are animal-model observations on a specific outcome — re-epithelialization in rats — not human dosing guidance or a recovery timeline for any person.

## Are there human clinical trials on TB-500?

No completed controlled trial exists for the TB-500 heptapeptide, for any indication [12]. Human data are limited to full-length synthetic Tβ4: a randomized, placebo-controlled Phase 1 intravenous safety and pharmacokinetics study in healthy volunteers (well tolerated up to 1260 mg) [6], and topical ophthalmic Tβ4 (RGN-259) studied for corneal healing and dry eye [11]. A registered injectable acute-MI Tβ4 trial completed; an early injectable trial was withdrawn. Efficacy of the 7-mer in humans is unproven.

## Thymosin beta-4: the parent protein behind TB-500

Thymosin beta-4 (gene `TMSB4X`, UniProt `P62328`) is a ubiquitous 43-amino-acid, ~4963 Da peptide and the body's principal G-actin-sequestering molecule [9]. It is present in nearly all human cells and released by platelets and macrophages at injury sites, where it is associated with cell migration, anti-scarring, anti-inflammatory and angiogenic activity [5]. TB-500 is its residues 17-23 — the actin-binding core. The reason this section exists at all is the recurring caveat: when a study says "thymosin beta-4," it almost always means this whole protein, not the fragment in commerce. Most of the findings on this page are, in that strict sense, `thymosin beta-4` findings — which is exactly why each one is logged with that distinction visible [12].

## Safety signals and open questions around TB-500

The largest open question is oncologic. Thymosin beta-4 is overexpressed in several cancers — pancreatic and colorectal among them — and is implicated in metastasis and tumor angiogenesis [9]. The same pro-migratory, pro-angiogenic properties that aid repair could, in principle, support tumor progression. This is a theoretical-but-serious signal, not a demonstrated harm of the fragment, and there are no long-term human safety data for TB-500 to weigh against it.

The `TB-500 side effects` picture is therefore mostly an absence of data rather than a catalog of events. Intravenous full-length Tβ4 was well tolerated to 1260 mg with no dose-limiting toxicities in the Phase 1 study [6], but that does not characterize the fragment, other routes, or chronic use. A 2026 *Sports Medicine* review flags scarce human safety data and the potential for serious harm for unapproved peptides including TB-500 [12]. A separate, practical concern is supply-side: the identity, purity and correct sequence of research-grade material are not guaranteed, which complicates interpreting any reported effect.

---

A developer-console reading of the TB-500 record — the actin-binding fragment logged against its studies, with the full-length thymosin beta-4 caveat flagged in every diff, no clinic behind the terminal and nothing here prescribed or sold.